Oncolysin B data

IMGN presented Phase I/II and Phase II trial results after ABMT, showing that 10 of 12 patients in the initial trial remained free of the disease, with the median time from treatment now more than three years.

Of 50 patients in the subsequent Phase II trial, who received the treatment as outpatients, 70 percent still are in remission after a median of 17 months. Historical data show that 30-50 percent of lymphoma patients undergoing ABMT stay free of disease after two years. ...